Webinar
Trinity Annual Drug Index Webinar
Your Choice of 3 Available Sessions: April 3 & April 8, 2025
Join us for expert discussion on the commercial performance and impact of novel drugs approved in 2021
Join your choice of 3 webinar sessions:
April 3rd | 12:00-12:45 PM ET
April 8th | 16:00-16:45 UTC+8 – Asia/Shanghai
April 8th | 15:00-15:45 CET – Europe/Berlin
2021 saw 40 unique drug and biologic approvals, of which ~33% (13/40) were Oncology, followed by ~18% (7/40) being Autoimmune and 10% (4/40) being Neurology. In this report we describe the notable themes and trends within the industry and take a deeper look at a few products with outstanding performance. Though the impact of the COVID-19 pandemic was primarily felt in 2020, 2021 fared worse than 2020 and sustained an ongoing decline in the relationship between a product’s therapeutic value and its commercial output.
